期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

溶血磷脂酸在卵巢癌细胞内HER2/neu的激活作用 被引量：2

The activation role of lysophospholipd acid in HER2/neu of human ovarian cancer cells
下载PDF
导出
摘要 目的探索溶血磷脂酸(LPA)在卵巢癌细胞内HER2/neu的激活作用。方法通过免疫沉淀反应和蛋白印迹法检测卵巢癌细胞中HER2的变化。结果 LPA能诱导卵巢癌细胞中HER2的快速和瞬态的磷酸化。结论 LPA在卵巢癌细胞中作为HER2的上游分子,对卵巢癌细胞有强有力的刺激,可诱导卵巢癌细胞中HER2磷酸化。 Objective The purpose of this study was to explore activation effect of lysophospholipd acid in HER2/neu of human ovarian cancer cell. Methods Changes of HER2 in ovarian cancer cells were analyzed by immune precipitation reaction and western blot. Results LPA can induce rapid and transient phosphorylation of HER2 in ovarian cancer cell. Conclusion LPA acts as upstream molecule of HER2 in ovarian cancer cell. The LPA may act as potent stimulator of ovarian cancer cell, and induce phosphorylation of HER2 in ovarian cancer cell.
作者 叶璐 刘斌 李书华 张艺
机构地区 广东省第二人民医院妇科 广州医学院病理教研室
出处 《临床和实验医学杂志》 2013年第8期570-571,共2页 Journal of Clinical and Experimental Medicine
基金 广东省医学科学技术研究基金课题(B2010053)
关键词 卵巢癌 溶血磷脂酸 HER2 NEU Ovarian cancer LPA HER2/neu
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Anliker B, Chun J. Cell surface receptors in lysophospholipid signaling [J]. Semin Cell Dev Biol, 2004,15(5) :457 -465.
  • 2Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid syn- thase (FAS) suppresses HER2/neu ( erbB - 2 ) oncogene overexpres- sion in cancer cells [J]. Proc Natl Acad Sci U S A, 2004,101(29) : 10715 - 10720.
  • 3Mayr D, Kanitz V, in ovarian tumours: Amann G, et al a comprehensive HER- 2/neu gene amplification and FISH a- nalysis on tissue microarrays [ J ]. Histopathology, 2006,48 (2) : 149 - 156.
  • 4Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER -2/neu expression in archival non - small cell lung carcinomas using FDA - approved Her- cep test [ J ]. Anticancer Res, 2000,20 (3 B) :2091 - 2096.
  • 5Seliger B, Rongcun Y, Atkins D, et al. HER -2/neu is expressed in human renal cellcarcinoma at heterogeneous levels independently of tumor gradingand staging and can be recognized by HLA - A2.1 - re- stricted cytotoxic T lymphocytes [ J ]. Int J Cancer, 2000,87 ( 3 ) : 349 - 359.
  • 6Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvantdoxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study [J]. J Clin Oncol, 2003,21 ( 1 ) :46 -53.
  • 7Li A J, Madden AC, Cass I,et al. The prognostic significance of throm- bocytosis in epithelial ovarian carcinoma [ J]. Gynecol Oncol, 2004,92 (1) :211 -214.
  • 8Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways [ J]. J Biol Chem, 2002,277(50) :48737 -48744.

同被引文献25

  • 1韦德英,汤春生.溶血磷脂酸与卵巢癌[J].现代妇产科进展,2004,13(4):297-299. 被引量：1
  • 2唐迪红,施小六,陈主初,周世权.HER-2/neu基因表达与卵巢上皮性癌的预后[J].医学临床研究,2004,21(6):600-602. 被引量：2
  • 3PIZER E S,THUPARI J,HAN W F,et al.Malonyl-coenzymeA is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cells and xenografts[J].Cancer Res,2000,60(2):213-218.
  • 4MAYR D,KANITZ V,AMANN G,et al.HER-2/neu gene amplification in ovarian tumours:a comprehensive immunohistochemical and FISH analysis on tissue microarrays[J].Histopathology,2006,48(2):149-156.
  • 5FELIP E,CAMPO JMD,RUBIO D,et al.Overexpression of cerbB-2 in epithelial ovarian cancer:prognostic value and relationship with response to chemotherapy[J].Cancer,1995,75(8):2147-2152.
  • 6Lori E W , John R L , Diljeet K S , et al. Survival a n d reproductive outco m e s in w o m e n treated for malignant ovarian g e r m cell tumors[J]. G y necologicO n c o l o g y , 2 0 1 1 , 1 2 1 ( 2 ) :2 8 5 - 2 8 9 .
  • 7S c h u m m e r M , Drescher C , Forrest R , et al. Evaluation of ovarian cancerremission markers H E 4 , M M P 7 an d Mesothelin by comparison to theestablished marker C A 1 2 5 [J] . Gynecol Oncol ,2012,125 (1) :65 - 6 9 .
  • 8Z h o n g J , K a n g J , W a n g X , et al. T A T - O S B P - 1 - M K K 6 ( E ) , a n o -vel T A T - fusion protein with high selectivity for h u m a n ovarian cancer,exhibits anti - tumor activity[J] . M e d O n c o l , 2 0 1 5 , 3 2 ( 4 ) :4 9 5 - 4 9 6 .
  • 9Z h o u B , S h u B , X i T , et al. D u b 3 expression correlates with t u m o r progressiona n d poor prognosis in h u m a n epithelial ovarian cancer[J]. Biom e d Pha r m a c o t h e r , 2 0 1 5 ,70 :8 4 - 89.
  • 10Y a o D , Lin Z , W u J. N e a r - Infrared Fluorogenic Probes with Polarity -Sensitive Emission for in Vivo Imaging of an Ovarian Cancer Biomarker[J], A C S A p p l Mater Interfaces, 2 0 1 6 , 8 ( 9 ) :5 8 4 7 - 5 8 5 6 .

引证文献2

二级引证文献26

临床和实验医学杂志
2013年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部